Results 171 to 180 of about 13,811 (304)

Interventional therapies for chronic heart failure: An overview of recent developments

ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu   +7 more
wiley   +1 more source

Association Between Discharge Medications and Oncologic Post-Embolization-Syndrome-Related Outcomes. [PDF]

Cancer Med
Li H, Moon J, Sim N, Horný M, Lima N, Konstantinidis M, Iyer D, Benenati S, Gichoya J, Newsome J, Bercu Z.   +10 more
europepmc   +1 more source

Stiripentol: Unpublished results from the first phase 2 clinical trial in Lennox–Gastaut syndrome conducted in the early 1990s

Epilepsia, EarlyView.
Abstract Objective This study was undertaken to present the results of an exploratory phase 2 trial of stiripentol in Lennox–Gastaut syndrome (LGS). Methods This exploratory single‐blind, single‐arm, nonrandomized sequential‐period phase 2 study was conducted at four centers in France between January 1989 and August 1993.
Stéphane Auvin, Benjamin Serraz, Jérémie Lespinasse, Laurent Chancharme   +3 more
wiley   +1 more source

Vestibular Suppressant Utilization and Subsequent Falls Among Patients 65 Years and Older With Dizziness in the United States. [PDF]

J Am Geriatr Soc
Marmor S, Karaca-Mandic P, Adams ME.
europepmc   +1 more source

A phase 3, randomized clinical trial of soticlestat as adjunctive therapy for Lennox–Gastaut syndrome

Epilepsia, EarlyView.
Soticlestat as adjunctive therapy for Lennox–Gastaut syndrome. Abstract Objective There remains a need for new treatments for Lennox–Gastaut syndrome (LGS), a developmental and epileptic encephalopathy with a heterogenous patient population that often requires polytherapy. The phase 3, randomized SKYWAY study (NCT04938427) investigated the efficacy and
Renzo Guerrini, Eric D. Marsh, Wei‐Ping Liao, Katsumi Imai, Ruzica Kravljanac, Anna Altmann, Cecil D. Hahn, Stéphane Auvin, Jimmy Schiemann, Yasir Khan, Pranab Mitra, Sarah I. Sheikh, Philipp von Rosenstiel, Mahnaz Asgharnejad, Dennis Dlugos, Venkatesha Murthy   +15 more
wiley   +1 more source

Contradictory and weak evidence on the effectiveness of anti-emetics for MTX-intolerance in JIA-patients

Pediatric Rheumatology Online Journal, 2018
Casper G. Schoemaker, E. H. Pieter van Dijkhuizen, Sebastiaan J. Vastert   +2 more
doaj   +1 more source

Comparative analysis of ingestion assessment methods in paraquat-poisoned patients. [PDF]

Eur J Med Res
Jin YL, Meng N, Wang M, Gao HB, Tian YP.
europepmc   +1 more source

Auriculo‐emetic reflex? [PDF]

Anaesthesia, 1989
openaire   +1 more source

Inherited metabolic epilepsies–established diseases, new approaches

Epilepsia Open, EarlyView.
Abstract Inherited metabolic epilepsies (IMEs) represent the inherited metabolic disorders (IMDs) in which epilepsy is a prevailing component, often determining other neurodevelopmental outcomes associated with the disorder. The different metabolic pathways affected by individual IMEs are the basis of their rarity and heterogeneity.
Itay Tokatly Latzer, Phillip L. Pearl
wiley   +1 more source

Drug interaction (27. anti-emetics during anti-cancer chemotherapy) [PDF]

, 2013
Aoyagi, Megumu, Fujiwara, Satoko, Kajizono, Makoto, Kitamura, Yoshihisa, Kurata, Yasuko, Sendo, Toshiaki   +5 more
core   +1 more source